Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- WEBSITE NEWS
January 17, 2005
- MEETING
January 17, 2005
- BULLTEIN
January 17, 2005
- New Year's Commentary -1-
January 17, 2005
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
January 17, 2005
- New Year's Commentary -2-
January 17, 2005
- OTC NEWS IN BRIEF
January 17, 2005
- Emerging New Therapeutics against Hypercholesterolemia and Atherosclerosis: Lipitor, a Golden Standard?
January 17, 2005
- DIAGNOSTIC NEWS IN BRIEF
January 17, 2005
- Kyorin to Accelerate Drug Discovery by Acquiring ABI
January 17, 2005
- WEBSITE NEWS
January 17, 2005
- Schering-Plough to Use New Formulation, New Evidence to Boost Sales of Claritin
January 3, 2005
- Eisai Recieves A Positive Opinion for Zonegran Approval from EMEA
January 3, 2005
- BUSINESS NEWS IN BRIEF
January 3, 2005
- DIAGNOSTIC NEWS IN BRIEF
January 3, 2005
- Reform Council, Korosho Finally Agree on "Mixed Medical Care"
January 3, 2005
- EDITOR'S NOTE
January 3, 2005
- 11 Ingredients/24 Products Including Add. Formulation Products
January 3, 2005
- Special interview
January 3, 2005
- REGULATORY NEWS IN BRIEF
January 3, 2005
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…